Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.

Autor:	Yutani, Shigeru1 yutani@med.kurume-u.ac.jp, Ueshima, Kazuomi2 kaz-ues@med.kindai.ac.jp, Abe, Kazumichi3 k-abe@fmu.ac.jp, Ishiguro, Atsushi4 ishikuro@cc.hirosaki-u.ac.jp, Eguchi, Junichi5 j.eguchi@med.showa-u.ac.jp, Matsueda, Satoko1 pines@med.kurume-u.ac.jp, Komatsu, Nobukazu6 kom@med.kurume-u.ac.jp, Shichijo, Shigeki1 shichijo@med.kurume-u.ac.jp, Yamada, Akira7 akiymd@med.kurume-u.ac.jp, Itoh, Kyogo1 kyogo@med.kurume-u.ac.jp, Sasada, Tetsuro1,6 tsasada@med.kurume-u.ac.jp, Kudo, Masatoshi2 m-kudo@med.kindai.ac.jp, Noguchi, Masanori7 noguchi@med.kurume-u.ac.jp
Zdroj:	Journal of Immunology Research. 10/11/2015, Vol. 2015, p1-8. 8p. 2 Charts, 2 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu